Table 3.
Responses and outcome by subtype and previous therapy.
| N (%), median [range] | ||||||||
|---|---|---|---|---|---|---|---|---|
| De novo (n=4) | Not De novo (n=38) | Prior TKI (n=31) | No prior TKI (n=11) | Prior BP therapy (n=5) | No prior BP therapy (n=38) | Same TKI as previous (n=20) | No same TKI as previous (n=22) | |
| CHR | 3 (75) | 35 (92) | 28 (90) | 10 (91) | 5 (100) | 34 (89) | 17 | 21 |
| CCyR | 2 (50) | 22 (58) | 17 (55) | 7 (64) | 2 (40) | 22 (58) | 7 | 17 |
| CMR | 0/3 (0) | 8/29 (28) | 4/23 (17) | 4/9 (44) | 0/3 (0) | 8/29 (28) | 3/12 | 5/20 |
| MMR | 0/3 (0) | 16/29 (56) | 10/23 (43) | 6/9 (67) | 0/3 (0) | 16/29 (55) | 4/12 | 12/20 |
| FC MRD (−) | NA | 7/12 (58) | 6/10 (60) | 1/2 (50) | NA | 7/12 (58) | 7/10 | 14/16 |
| RD (months) | 14 [5–68] | NR | 67 [38–62] | NR | 14 [3–25] | NR | 14 [5–23] | NR |
| OS (months) | 10 [1–30] | 17 [5–29] | 17 [6–28] | 17 [1–61] | 14 [5–23] | 17 [1–61] | 12 [7–17] | 59 [3–134] |
NA: not assessable; NR: not reached; RD: remission duration; OS: overall survival